Latest Stock Buy or Sell? Make More Informed Decisions!

This one has 50 of the biggest names in Europe. Europe and Asia would be the bulk of the international markets.

Not sure if you can be in Asia without being in China. A lot of names have the growth coming from China or Hong Kong. AIA is a good name, with 50 of the largest names in that region, including China (34%) and Taiwan (31%).

For Japan, EWJ is one to use.

When investing in Asia, he just goes with the large caps and doesn't use any of the mid-cap names.

Not sure if you can be in Asia without being in China. A lot of names have the growth coming from China or Hong Kong. AIA is a good name, with 50 of the largest names in that region, including China (34%) and Taiwan (31%).

For Japan, EWJ is one to use.

When investing in Asia, he just goes with the large caps and doesn't use any of the mid-cap names.

All the names have been performing well. Improved profitability in 2023 sets the stage for continued growth going forward. Focusing on menu innovation and digital transformation through mobile apps. Franchise business model offers stability and good cashflow visibility. Track record of increasing dividends and share buybacks. Yield is 3.1%, expected to grow modestly over the next few years.

Chart shows ascending pattern of higher highs and higher lows, technically solid. Shares outpacing the TSX since mid-2022. Seeing a 9-10% earnings growth rate.

Shares down 16-17%, near 200-day MA, opportunity. Very strong brand reputation, dominant market position. Very consistent revenue growth. Short term, still sees pretty stable US housing market, consumer confidence remains stable. US labour market remains steady, with low unemployment. Interest rates will be lower at some point. Yield is 2.7%, very consistent dividend increases.

Homes are aging, shortage in home inventory, home prices still going higher. Very resilient during downturns, home maintenance needs continue regardless of what's going on.

Leader, controls 1/3 of the industry. Virtual triopoly gives them leverage and predictable cashflow. Population is aging. At least 60% of Americans use at least 1 drug, and this will increase over time. High-demand segments such as weight loss and diabetes are rising, which will increase demand for its logistics and distribution. Yield is 0.5%.

Increased share buybacks last summer. Beat top and bottom on last results. Upped guidance for 2024. Share price trending higher, above 200-day and 200-week MAs. Has beat S&P since early 2019. About 12% earnings growth rate. Classic, steady healthcare name to own.